NASDAQ:CLDX Celldex Therapeutics (CLDX) Stock Forecast, Price & News $25.45 -0.79 (-3.01%) (As of 05:24 PM ET) Add Compare Share Share Today's Range$25.19▼$26.3450-Day Range$26.24▼$37.4052-Week Range$25.19▼$48.40Volume435,198 shsAverage Volume508,771 shsMarket Capitalization$1.20 billionP/E RatioN/ADividend YieldN/APrice Target$63.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Celldex Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside148.9% Upside$63.33 Price TargetShort InterestBearish13.33% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.64) to ($3.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.32 out of 5 starsMedical Sector929th out of 968 stocksDiagnostic Substances Industry11th out of 12 stocks 3.3 Analyst's Opinion Consensus RatingCelldex Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $63.33, Celldex Therapeutics has a forecasted upside of 148.9% from its current price of $25.45.Amount of Analyst CoverageCelldex Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.33% of the outstanding shares of Celldex Therapeutics have been sold short.Short Interest Ratio / Days to CoverCelldex Therapeutics has a short interest ratio ("days to cover") of 13.5, which indicates bearish sentiment.Change versus previous monthShort interest in Celldex Therapeutics has recently decreased by 3.67%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCelldex Therapeutics does not currently pay a dividend.Dividend GrowthCelldex Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLDX. Previous Next 1.1 News and Social Media Coverage Search Interest4 people have searched for CLDX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows2 people have added Celldex Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Celldex Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.70% of the stock of Celldex Therapeutics is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Celldex Therapeutics are expected to decrease in the coming year, from ($2.64) to ($3.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Celldex Therapeutics is -10.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Celldex Therapeutics is -10.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCelldex Therapeutics has a P/B Ratio of 3.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Celldex Therapeutics (NASDAQ:CLDX) StockCelldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. It has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Read More CLDX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLDX Stock News HeadlinesAugust 22, 2023 | msn.comWells Fargo Initiates Coverage of Celldex Therapeutics (CLDX) with Underweight RecommendationAugust 22, 2023 | msn.comWells Fargo starts Celldex at underweight, cites over-optimism for hives drugSeptember 22, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...August 17, 2023 | msn.comCantor Fitzgerald Reiterates Celldex Therapeutics (CLDX) Overweight RecommendationAugust 11, 2023 | msn.comCelldex Therapeutics: Promising Phase 1b Results For Barzolvolimab In CSUAugust 9, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Celldex (CLDX)August 8, 2023 | finance.yahoo.comCelldex Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateJuly 11, 2023 | finance.yahoo.comCelldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous UrticariaSeptember 22, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...July 1, 2023 | finance.yahoo.comCLDX- Encouraging Data on CSU Drug Could be Followed by More CatalystsJune 14, 2023 | markets.businessinsider.comSVB Securities Remains a Buy on Celldex (CLDX)June 10, 2023 | finance.yahoo.comCelldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023June 8, 2023 | finance.yahoo.comCelldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023May 31, 2023 | markets.businessinsider.com4 Analysts Have This to Say About Celldex TherapeuticsMay 31, 2023 | finance.yahoo.comCelldex Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced MalignanciesMay 23, 2023 | finance.yahoo.comCelldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth PlansMay 18, 2023 | seekingalpha.comCelldex Therapeutics: Revolutionizing Cancer Care With Innovative ImmunotherapiesMay 15, 2023 | finance.yahoo.comCelldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622 at IMMUNOLOGY2023™May 6, 2023 | msn.comCantor Fitzgerald Maintains Celldex Therapeutics (CLDX) Overweight RecommendationMay 5, 2023 | msn.comHC Wainwright & Co. Reiterates Celldex Therapeutics (CLDX) Buy RecommendationMay 4, 2023 | msn.comCelldex Therapeutics: Q1 Earnings InsightsMay 4, 2023 | finance.yahoo.comCelldex Reports First Quarter 2023 Financial Results and Provides Corporate UpdateApril 18, 2023 | finance.yahoo.comStrength Seen in Celldex (CLDX): Can Its 7.1% Jump Turn into More Strength?April 12, 2023 | benzinga.comIs Celldex Therapeutics, Inc. (CLDX) a Smart Choice in Biotechnology Monday?April 12, 2023 | finance.yahoo.comAre Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 42%?March 23, 2023 | markets.businessinsider.comLifeSci Capital Reaffirms Their Buy Rating on Celldex (CLDX)March 22, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Celldex (CLDX)See More Headlines Receive CLDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celldex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CLDX Company Calendar Last Earnings8/08/2023Today9/22/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:CLDX CUSIP15117B10 CIK744218 Webwww.celldex.com Phone(908) 454-7120Fax908-454-1911Employees148Year Founded1983Price Target and Rating Average Stock Price Forecast$63.33 High Stock Price Forecast$73.00 Low Stock Price Forecast$54.00 Forecasted Upside/Downside+141.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,320,000.00 Net Margins-3,475.70% Pretax Margin-3,475.70% Return on Equity-36.15% Return on Assets-33.63% Debt Debt-to-Equity RatioN/A Current Ratio16.93 Quick Ratio16.93 Sales & Book Value Annual Sales$2.36 million Price / Sales525.47 Cash FlowN/A Price / Cash FlowN/A Book Value$6.93 per share Price / Book3.79Miscellaneous Outstanding Shares47,260,000Free Float45,512,000Market Cap$1.24 billion OptionableOptionable Beta2.14 Social Links The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Anthony S. Marucci M.B.A. (Age 61)Founder, Pres, CEO & Director Comp: $1.14MDr. Tibor Keler (Age 64)Founder, Chief Scientific Officer & Exec. VP Comp: $739.03kMr. Sam Martin (Age 52)Sr. VP, CFO, Sec. & Treasurer Comp: $617.26kDr. Margo Heath-Chiozzi M.D. (Age 66)Sr. VP of Regulatory Affairs Comp: $614.12kDr. Diane C. Young M.D. (Age 66)Sr. VP & Chief Medical Officer Comp: $643.5kProf. Joseph P. Schlessinger Ph.D. (Age 78)Co-Founder & Member of Scientific Advisory Board Ms. Sarah Cavanaugh (Age 48)Sr. VP of Corp. Affairs & Admin. Patrick TillSr. Director of Investor Relations & Corp. CommunicationsMr. Freddy A. Jimenez Esq. (Age 54)Sr. VP & Gen. Counsel Dr. Ronald A. Pepin (Age 67)Chief Bus. Officer & Sr. VP More ExecutivesKey CompetitorsMyriad GeneticsNASDAQ:MYGNIntellia TherapeuticsNASDAQ:NTLALantheusNASDAQ:LNTHNeogenNASDAQ:NEOGOwens & MinorNYSE:OMIView All CompetitorsInstitutional OwnershipWolverine Trading LLCBought 14,200 shares on 8/23/2023Ownership: 0.000%Affinity Asset Advisors LLCBought 37,031 shares on 8/21/2023Ownership: 0.184%California State Teachers Retirement SystemBought 611 shares on 8/21/2023Ownership: 0.107%Teachers Retirement System of The State of KentuckyBought 6,090 shares on 8/21/2023Ownership: 0.061%Nuveen Asset Management LLCBought 420 shares on 8/16/2023Ownership: 0.256%View All Institutional Transactions CLDX Stock - Frequently Asked Questions Should I buy or sell Celldex Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last year. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CLDX shares. View CLDX analyst ratings or view top-rated stocks. What is Celldex Therapeutics' stock price forecast for 2023? 4 Wall Street research analysts have issued 1 year price targets for Celldex Therapeutics' shares. Their CLDX share price forecasts range from $54.00 to $73.00. On average, they expect the company's stock price to reach $63.33 in the next twelve months. This suggests a possible upside of 141.4% from the stock's current price. View analysts price targets for CLDX or view top-rated stocks among Wall Street analysts. How have CLDX shares performed in 2023? Celldex Therapeutics' stock was trading at $44.57 at the beginning of 2023. Since then, CLDX shares have decreased by 41.1% and is now trading at $26.24. View the best growth stocks for 2023 here. When is Celldex Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our CLDX earnings forecast. How were Celldex Therapeutics' earnings last quarter? Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced its earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.65). The biopharmaceutical company had revenue of $0.27 million for the quarter, compared to the consensus estimate of $0.67 million. Celldex Therapeutics had a negative net margin of 3,475.70% and a negative trailing twelve-month return on equity of 36.15%. What ETFs hold Celldex Therapeutics' stock? ETFs with the largest weight of Celldex Therapeutics (NASDAQ:CLDX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO).SPDR S&P Biotech ETF (XBI). When did Celldex Therapeutics' stock split? Celldex Therapeutics's stock reverse split on Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 8th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Celldex Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include OPKO Health (OPK), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP), Precigen (PGEN), Micron Technology (MU), Dynavax Technologies (DVAX), Exelixis (EXEL), bluebird bio (BLUE) and SCYNEXIS (SCYX). What is Celldex Therapeutics' stock symbol? Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX." Who are Celldex Therapeutics' major shareholders? Celldex Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.82%), State Street Corp (5.77%), Kynam Capital Management LP (5.50%), Polar Capital Holdings Plc (5.11%), Jennison Associates LLC (2.81%) and Point72 Asset Management L.P. (2.51%). Insiders that own company stock include Diane C Young, Elizabeth Crowley, Freddy A Jimenez, Richard M Wright, Samuel Bates Martin and Sarah Cavanaugh. View institutional ownership trends. How do I buy shares of Celldex Therapeutics? Shares of CLDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Celldex Therapeutics' stock price today? One share of CLDX stock can currently be purchased for approximately $26.24. How much money does Celldex Therapeutics make? Celldex Therapeutics (NASDAQ:CLDX) has a market capitalization of $1.24 billion and generates $2.36 million in revenue each year. The biopharmaceutical company earns $-112,320,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis. How many employees does Celldex Therapeutics have? The company employs 148 workers across the globe. How can I contact Celldex Therapeutics? Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The official website for the company is www.celldex.com. The biopharmaceutical company can be reached via phone at (908) 454-7120, via email at ir@celldextherapeutics.com, or via fax at 908-454-1911. This page (NASDAQ:CLDX) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.